Skip to main content
. 2012 Nov 12;199(4):583–588. doi: 10.1083/jcb.201210077

Figure 2.

Figure 2.

Structure and mechanism of action of proteasome inhibitors. (A) Structure of MG132, an inhibitor widely used in uncovering many cellular functions of the proteasome. (B and C) Structure of bortezomib (B), the inhibitor used to treat multiple myeloma, and its chemical reaction with the active site terminal threonine residue of the β5 subunit (C). (D) The primary mechanisms by which bortezomib causes death of myeloma cells.